Researchers Explore Trikafta in Younger Patients

Researchers Explore Trikafta in Younger Patients

303948

Researchers Explore Trikafta in Younger Patients

Researchers at the Children’s Hospital Colorado Breathing Institute are participating in four new studies to evaluate the long-term impact of Trikafta (elexacaftor, tezacaftor, and ivacaftor) in people with cystic fibrosis (CF) ages 6 and older, its effectiveness in infants and children younger than 6, and to find alternative treatments for those who don’t qualify for the therapy based on underlying genetic mutations. The team, led by Edith Zemanick, MD, a pediatric pulmonologist, joined a Phase…

You must be logged in to read/download the full post.